IP Library › Granted Patent US 12,297,277
Granted Patent B2
US 12,297,277 · App. 17/836,707 · Granted May 13, 2025

Anti-sortilin antibodies and methods of use thereof

Inventors: Tina Schwabe (San Francisco, CA); Michael Kurnellas (San Francisco, CA); Arnon Rosenthal (Woodside, CA); Robert Pejchal (Lebanon, NH); Anthony B. Cooper (White River Junction, VT)
Assignee: Alector LLC
C07K16/286C07K2317/31C07K2317/52C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,277
App. No.
17/836,707
Granted
May 13, 2025
Kind
B2
Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Claims (94)

1. An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that binds to a Sortilin protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein:

(a) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIQQGYYGMDV (SEQ ID NO: 5); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32);

(b) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIQQGYYGMDV (SEQ ID NO: 5); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRVS (SEQ ID NO: 30), and an HVR-L3 comprising the amino acid sequence MQQQETPLT (SEQ ID NO: 33);

(c) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLES (SEQ ID NO: 3), an HVR-H3 comprising the amino acid sequence ARQGSIQQGYYGMDV (SEQ ID NO: 5); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32);

(d) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32);

(e) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSTGYNYLD (SEQ ID NO: 9), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32);

(f) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQETPLT (SEQ ID NO: 33);

(g) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIQQGYYGMDV (SEQ ID NO: 5); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLHSNGYNYLD (SEQ ID NO: 26), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQETPLT (SEQ ID NO: 33);

(h) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQGLLRSNGYNYLD (SEQ ID NO: 27), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32);

(i) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSSGYNYLD (SEQ ID NO: 10), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32); or

(j) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSIGYNYLD (SEQ ID NO: 21), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32).

2. A vector comprising the nucleic acid of claim 1 .

3. An isolated host cell comprising the vector of claim 2 .

4. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 3 so that the antibody is produced.

5. The method of claim 4 , further comprising recovering the antibody produced by the host cell.

6. The nucleic acid of claim 1 , wherein the antibody:

(a) decreases cell surface levels of Sortilin more than the level of decrease caused by an anti-Sortilin antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 56 and a light chain variable region comprising the sequence of SEQ ID NO: 79;

(b) increases extracellular levels of Progranulin more than the level of increase caused by an anti-Sortilin antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 56 and a light chain variable region comprising the sequence of SEQ ID NO: 79;

(c) inhibits the interaction between Sortilin expressed on a cell and Progranulin more than the level of inhibition caused by an anti-Sortilin antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 56 and a light chain variable region comprising the sequence of SEQ ID NO: 79; or

(d) any combination of (a)-(c).

7. The nucleic acid of claim 1 , wherein the antibody:

(a) has a dissociation constant (K D ) for human Sortilin that is at least 1.1-fold lower than an anti-Sortilin antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 56 and a light chain variable region comprising the sequence of SEQ ID NO: 79, wherein the K D is determined by FACS; and/or

(b) has a dissociation constant (K D ) for human Sortilin that ranges from about 5.0E-10 M to about 1.0E-9 M wherein the K D is determined by FACS, or about 250-500 pM wherein the K D is determined by Bio-layer interferometry.

8. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), and an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSTGYNYLD (SEQ ID NO: 9), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32).

9. A vector comprising the nucleic acid of claim 8 .

10. An isolated host cell comprising the vector of claim 9 .

11. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 10 so that the antibody is produced.

12. The method of claim 11 , further comprising recovering the antibody produced by the host cell.

13. The nucleic acid of claim 8 , wherein the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering.

14. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), and an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSNGYNYLD (SEQ ID NO: 8), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32).

15. The nucleic acid of claim 1 , wherein the antibody comprises:

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57;

(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 58;

(c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 59;

(d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 55, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57;

(e) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 55, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 58;

(f) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57;

(g) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77;

(h) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 78;

(i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 79;

(j) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80;

(k) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60;

(l) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 61; or

(m) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 72.

16. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 60.

17. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57.

18. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 137 and a light chain comprising the amino acid sequence of SEQ ID NO: 142.

19. The nucleic acid of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 138 and a light chain comprising the amino acid sequence of SEQ ID NO: 142.

20. The nucleic acid of claim 1 , wherein the antibody is of the IgG class, the IgM class, or the IgA class.

21. The nucleic acid of claim 20 , wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype.

22. The nucleic acid of claim 21 , wherein:

(a) the antibody has an IgG1 or IgG2 isotype and comprises an Fc region comprising an amino acid substitution at position P331S, wherein the numbering of the residue position is according to EU numbering;

(b) the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering;

(c) the antibody has an IgG1, IgG2, or IgG4 isotype and comprises an Fc region comprising an amino acid substitution at position N297A, wherein the numbering of the residue position is according to EU numbering; or

(d) comprises an Fc region comprising an amino acid substitution at positions S267E and L328F, wherein the numbering of the residue position is according to EU numbering.

23. The nucleic acid of claim 21 , wherein the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering.

24. The nucleic acid of claim 1 , wherein the Sortilin protein is a human Sortilin protein.

25. The nucleic acid of claim 24 , wherein the human Sortilin protein comprises the amino acid sequence of SEQ ID NO: 81.

26. The nucleic acid of claim 1 , wherein the Sortilin protein is a wild-type protein, a naturally occurring variant, or a disease variant.

27. The nucleic acid of claim 1 , wherein the antibody is a human antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, or a conjugated antibody.

28. The nucleic acid of claim 27 , wherein the antibody is a bispecific antibody recognizing a first antigen and a second antigen.

29. The nucleic acid of claim 28 , wherein the first antigen is the Sortilin protein and the second antigen is an antigen facilitating transport across the blood-brain-barrier.

30. The nucleic acid of claim 29 , wherein the second antigen is selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, a llama single domain antibody, TMEM 30 (A), a protein transduction domain, TAT, Syn-B, penetratin, a poly-arginine peptide, an angiopep peptide, basigin, Glut1, CD98hc, and ANG1005.

31. The nucleic acid of claim 1 , wherein the antibody is an antibody fragment that binds to a human Sortilin protein.

32. The nucleic acid of claim 31 , wherein the antibody fragment is an Fab, Fab′, Fab′-SH, F (ab′) 2, Fv, or scFv fragment.

33. An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that binds to a Sortilin protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 56 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 60.

34. The nucleic acid of claim 33 , wherein the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering.

35. A vector comprising the nucleic acid of claim 33 .

36. An isolated host cell comprising the vector of claim 35 .

37. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 36 so that the antibody is produced.

38. The method of claim 37 , further comprising recovering the antibody produced by the host cell.

39. An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that binds to a Sortilin protein, wherein the antibody comprises a light chain variable region comprising:

(a) an HVR-L1 comprising the amino acid sequence RSSQSLLRSTGYNYLD (SEQ ID NO: 9), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32); or

(b) the amino acid sequence of SEQ ID NO: 60.

40. A vector comprising the nucleic acid of claim 39 .

41. An isolated host cell comprising the vector of claim 40 .

42. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 41 so that the antibody is produced.

43. The method of claim 42 , further comprising recovering the antibody produced by the host cell.

44. An isolated host cell comprising nucleic acid encoding an antibody that binds to a Sortilin protein, wherein the host cell comprises:

(a) a first nucleic acid encoding a polypeptide comprising a heavy chain variable region, wherein the heavy chain variable region comprises:

i. an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), and an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); or

ii. the amino acid sequence of SEQ ID NO: 56; and

(b) a second nucleic acid encoding a polypeptide comprising a light chain variable region, wherein the light chain variable region comprises:

i. an HVR-L1 comprising the amino acid sequence RSSQSLLRSTGYNYLD (SEQ ID NO: 9), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32); or

ii. the amino acid sequence of SEQ ID NO: 60.

45. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 44 so that the antibody is produced.

46. The method of claim 45 , further comprising recovering the antibody produced by the host cell.

47. The isolated host cell of claim 44 , wherein the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering.

48. An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that binds to a Sortilin protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence YSISSGYYWG (SEQ ID NO: 1), an HVR-H2 comprising the amino acid sequence TIYHSGSTYYNPSLKS (SEQ ID NO: 2), an HVR-H3 comprising the amino acid sequence ARQGSIKQGYYGMDV (SEQ ID NO: 6); and the light chain variable region comprises an HVR-L1 comprising the amino acid sequence RSSQSLLRSTGYNYLD (SEQ ID NO: 9), an HVR-L2 comprising the amino acid sequence LGSNRAS (SEQ ID NO: 29), and an HVR-L3 comprising the amino acid sequence MQQQEAPLT (SEQ ID NO: 32).

49. The nucleic acid of claim 48 , wherein the antibody has an IgG1 isotype and comprises an Fc region comprising amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of the residue position is according to EU numbering.

50. A vector comprising the nucleic acid of claim 49 .

51. An isolated host cell comprising the vector of claim 50 .

52. A method of producing an antibody that binds to a Sortilin protein, comprising culturing the host cell of claim 51 so that the antibody is produced.

53. The method of claim 52 , further comprising recovering the antibody produced by the host cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2022
From: SCHWABE, TINA; KURNELLAS, MICHAEL; ROSENTHAL, ARNON
To: ALECTOR LLC
Reel/Frame 060339/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2022
From: PEJCHAL, ROBERT; COOPER, ANTHONY B.
To: ADIMAB LLC
Reel/Frame 060339/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2022
From: ADIMAB LLC
To: ALECTOR LLC
Reel/Frame 060339/0152 →
Continuity (5)
Division 16510773 · Jul 12, 2019
Provisional Application 62868849 · Jun 28, 2019
Provisional Application 62860184 · Jun 11, 2019
Provisional Application 62698007 · Jul 13, 2018
Related Publication 20220348656A1 · Nov 3, 2022
References Cited (400)
US RE30985E · Cartaya · 1982 [cited by applicant]
US 4560655A · Baker · 1985 [cited by applicant]
US 4657760A · Kung et al. · 1987 [cited by applicant]
US 4657866A · Kumar · 1987 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4767704A · Cleveland et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4927762A · Darfler · 1990 [cited by applicant]
US 5122469A · Mather et al. · 1992 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5225212A · Martin et al. · 1993 [cited by applicant]
US 5229275A · Goroff et al. · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5567610A · Borrebaeck et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571894A · Wels et al. · 1996 [cited by applicant]
US 5573905A · Lerner et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5587458A · King et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648237A · Carter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5789199A · Joly et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5840523A · Simmons et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5869619A · Studnicka · 1999 [cited by applicant]
US 5959177A · Hein et al. · 1999 [cited by applicant]
US 6040498A · Stomp et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6417429B1 · Hein et al. · 2002 [cited by applicant]
US 6420548B1 · Vézina et al. · 2002 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7041870B2 · Tomizuka et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7125978B1 · Vézina et al. · 2006 [cited by applicant]
US 7189826B2 · Rodman · 2007 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 8008009B2 · Choquet-Kastylevsky et al. · 2011 [cited by applicant]
US 8066997B2 · Nykjaer et al. · 2011 [cited by applicant]
US 8460657B2 · Nykjaer et al. · 2013 [cited by applicant]
US 8614299B2 · Baurin et al. · 2013 [cited by applicant]
US 8703125B2 · Pedersen et al. · 2014 [cited by applicant]
US 8748384B2 · Andersen et al. · 2014 [cited by applicant]
US 8795627B2 · Starr et al. · 2014 [cited by applicant]
US 8815808B2 · Nykjaer et al. · 2014 [cited by applicant]
US 8877714B2 · Starr et al. · 2014 [cited by applicant]
US 8986690B2 · Nykjaer et al. · 2015 [cited by applicant]
US 9061045B2 · Choquet-Kastylevsky et al. · 2015 [cited by applicant]
US 9062126B2 · Zankel et al. · 2015 [cited by applicant]
US 9084745B2 · Nykjaer et al. · 2015 [cited by applicant]
US 9234036B2 · Anderson et al. · 2016 [cited by applicant]
US 9605073B2 · Nykjaer et al. · 2017 [cited by applicant]
US 9670263B2 · Pedersen et al. · 2017 [cited by applicant]
US 9822366B2 · Aikawa et al. · 2017 [cited by applicant]
US 10087255B2 · Rosenthal et al. · 2018 [cited by applicant]
US 10308718B2 · Rosenthal et al. · 2019 [cited by applicant]
US 10428150B2 · Rosenthal et al. · 2019 [cited by applicant]
US 10478421B1 · Sparks et al. · 2019 [cited by applicant]
US 10849896B2 · Patel et al. · 2020 [cited by applicant]
US 10849992B1 · Rosenthal et al. · 2020 [cited by applicant]
US 11186645B2 · Rosenthal et al. · 2021 [cited by applicant]
US 11208488B2 · Rosenthal et al. · 2021 [cited by applicant]
US 11339223B2 · Rosenthal et al. · 2022 [cited by applicant]
US 11396546B2 · Schwabe et al. · 2022 [cited by applicant]
US 20020164328A1 · Shinkawa et al. · 2002 [cited by applicant]
US 20030115614A1 · Kanda et al. · 2003 [cited by applicant]
US 20030157108A1 · Presta · 2003 [cited by applicant]
US 20040093621A1 · Shitara et al. · 2004 [cited by applicant]
US 20040109865A1 · Niwa et al. · 2004 [cited by applicant]
US 20040110282A1 · Kanda et al. · 2004 [cited by applicant]
US 20040110704A1 · Yamane et al. · 2004 [cited by applicant]
US 20040132140A1 · Satoh et al. · 2004 [cited by applicant]
US 20060025576A1 · Miller et al. · 2006 [cited by applicant]
US 20070061900A1 · Murphy et al. · 2007 [cited by applicant]
US 20070148167A1 · Strohl · 2007 [cited by applicant]
US 20070292936A1 · Barthelemy et al. · 2007 [cited by applicant]
US 20080069820A1 · Fuh et al. · 2008 [cited by applicant]
US 20090002360A1 · Chen et al. · 2009 [cited by applicant]
US 20090055944A1 · Korman et al. · 2009 [cited by applicant]
US 20090068200A1 · Choquet-Kastylevsky et al. · 2009 [cited by applicant]
US 20090181855A1 · Vasquez et al. · 2009 [cited by applicant]
US 20100028333A1 · Getty et al. · 2010 [cited by applicant]
US 20100056386A1 · Vasquez et al. · 2010 [cited by applicant]
US 20100092481A1 · Lanzavecchia et al. · 2010 [cited by applicant]
US 20100280227A1 · Ambrose et al. · 2010 [cited by applicant]
US 20120039865A1 · Strittmatter et al. · 2012 [cited by applicant]
US 20120315244A1 · Yuan et al. · 2012 [cited by applicant]
US 20130115222A1 · Hempstead et al. · 2013 [cited by applicant]
US 20130171173A1 · Choquet-Kastylevsky et al. · 2013 [cited by applicant]
US 20130336988A1 · Hempstead et al. · 2013 [cited by applicant]
US 20140004108A1 · Yuan et al. · 2014 [cited by applicant]
US 20150299304A1 · Nykjaer et al. · 2015 [cited by applicant]
US 20160024172A1 · Zankel et al. · 2016 [cited by applicant]
US 20160060346A1 · Andersen et al. · 2016 [cited by applicant]
US 20160194631A1 · Yuan et al. · 2016 [cited by applicant]
US 20160349276A1 · Jepsen et al. · 2016 [cited by applicant]
US 20170049855A1 · Liu et al. · 2017 [cited by applicant]
US 20170096486A1 · Landberg · 2017 [cited by applicant]
US 20170158766A1 · Nykjaer et al. · 2017 [cited by applicant]
US 20170210808A1 · Rosenthal et al. · 2017 [cited by applicant]
US 20170240611A1 · Pedersen et al. · 2017 [cited by applicant]
US 20170246263A1 · Concino et al. · 2017 [cited by applicant]
US 20170267761A1 · Ronn et al. · 2017 [cited by applicant]
US 20170318057A1 · Nykjaer et al. · 2017 [cited by applicant]
US 20180265586A1 · Rosenthal et al. · 2018 [cited by applicant]
US 20190023788A1 · Ronn et al. · 2019 [cited by applicant]
US 20190062433A1 · Rosenthal et al. · 2019 [cited by applicant]
US 20190085084A1 · Rosenthal et al. · 2019 [cited by applicant]
US 20190127475A1 · Rosenthal et al. · 2019 [cited by applicant]
US 20200024348A1 · Schwabe et al. · 2020 [cited by applicant]
US 20200223928A1 · Rosenthal et al. · 2020 [cited by applicant]
US 20200330553A1 · Ito et al. · 2020 [cited by applicant]
US 20200392229A1 · Paul et al. · 2020 [cited by applicant]
US 20220185898A1 · Rosenthal et al. · 2022 [cited by applicant]
US 20220185899A1 · Rosenthal et al. · 2022 [cited by applicant]
US 20220251219A1 · Rosenthal et al. · 2022 [cited by applicant]
US 20230047941A1 · Schwabe et al. · 2023 [cited by applicant]
US 20240101681A1 · Rosenthal et al. · 2024 [cited by applicant]
US 20240132597A1 · Paul et al. · 2024 [cited by applicant]
CN 101835489A · 2010 [cited by applicant]
EP 308936B1 · 1994 [cited by applicant]
EP 404097B1 · 1996 [cited by applicant]
EP 546073B1 · 1997 [cited by applicant]
JP 2014519517A · 2014 [cited by applicant]
JP 2018517401A · 2018 [cited by applicant]
WO WO198700195A1 · 1987 [cited by applicant]
WO WO198704462A1 · 1987 [cited by applicant]
WO WO199003430A1 · 1990 [cited by applicant]
WO WO199100360A1 · 1991 [cited by applicant]
WO WO199110741A1 · 1991 [cited by applicant]
WO WO199220373A1 · 1992 [cited by applicant]
WO WO199301161A1 · 1993 [cited by applicant]
WO WO199308829A1 · 1993 [cited by applicant]
WO WO199311161A1 · 1993 [cited by applicant]
WO WO199316185A2 · 1993 [cited by applicant]
WO WO199404690A1 · 1994 [cited by applicant]
WO WO199627011A1 · 1996 [cited by applicant]
WO WO199633735A1 · 1996 [cited by applicant]
WO WO199634096A1 · 1996 [cited by applicant]
WO WO199711971A1 · 1997 [cited by applicant]
WO WO199717852A1 · 1997 [cited by applicant]
WO WO199824893A2 · 1998 [cited by applicant]
WO WO199958572A1 · 1999 [cited by applicant]
WO WO2004042072A2 · 2004 [cited by applicant]
WO WO2004056385A2 · 2004 [cited by applicant]
WO WO2005044293A2 · 2005 [cited by applicant]
WO WO2006138343A2 · 2006 [cited by applicant]
WO WO2007035716A2 · 2007 [cited by applicant]
WO WO2007088305A1 · 2007 [cited by applicant]
WO WO2007106585A1 · 2007 [cited by applicant]
WO WO2008036682A2 · 2008 [cited by applicant]
WO WO2008052016A2 · 2008 [cited by applicant]
WO WO2008074329A2 · 2008 [cited by applicant]
WO WO2008076262A2 · 2008 [cited by applicant]
WO WO2008079246A2 · 2008 [cited by applicant]
WO WO2008086452A2 · 2008 [cited by applicant]
WO WO2009036379A2 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2009132656A2 · 2009 [cited by applicant]
WO WO2009140972A2 · 2009 [cited by applicant]
WO WO2009155932A2 · 2009 [cited by applicant]
WO WO2010022175A1 · 2010 [cited by applicant]
WO WO2010028333A2 · 2010 [cited by applicant]
WO WO2010069331A2 · 2010 [cited by applicant]
WO WO2010105256A1 · 2010 [cited by applicant]
WO WO2011041582A2 · 2011 [cited by applicant]
WO WO2011159762A1 · 2011 [cited by applicant]
WO WO2012009568A2 · 2012 [cited by applicant]
WO WO2012068332A2 · 2012 [cited by applicant]
WO WO2013026833A1 · 2012 [cited by applicant]
WO WO2012171057A1 · 2012 [cited by applicant]
WO WO2014071131A1 · 2014 [cited by applicant]
WO WO2014179363A1 · 2014 [cited by applicant]
WO WO2015006504A1 · 2015 [cited by applicant]
WO WO2015119989A1 · 2015 [cited by applicant]
WO WO2015121166A1 · 2015 [cited by applicant]
WO WO2015144860A1 · 2015 [cited by applicant]
WO WO2015147506A1 · 2015 [cited by applicant]
WO WO2016025523A1 · 2016 [cited by applicant]
WO WO2016164608A1 · 2016 [cited by applicant]
WO WO2016164637A1 · 2016 [cited by applicant]
WO WO2017009327A1 · 2017 [cited by applicant]
WO WO2017024137A1 · 2017 [cited by applicant]
WO WO2018191786A1 · 2018 [cited by applicant]
WO WO2019016247A2 · 2019 [cited by applicant]
WO WO2019246071A1 · 2019 [cited by applicant]
WO WO2020014617A1 · 2020 [cited by applicant]
WO WO2020037434A1 · 2020 [cited by applicant]
WO WO2020051624A1 · 2020 [cited by applicant]
WO WO2020120749A1 · 2020 [cited by applicant]
WO WO2020191212A1 · 2020 [cited by applicant]
WO WO2020252066A1 · 2020 [cited by applicant]
Alegre et al. (1994). “A Non-Activating “Humanized” Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties In Vivo,” Transplantation 57(11):1537-1543. [cited by applicant]
Almagro et al. (2008). “Humanization of Antibodies,” Frontiers in Bio-Science 13:1619-1633. [cited by applicant]
Al-Shawi et al. (2007). “ProNGF, Sortilin, and Age-Related Neurodegeneration,” Annals of the New York Academy of Sciences, pp. 208-215. [cited by applicant]
Al-Shawi et al. (2008). “Neurotoxic and Neurotrophic Roles of proNGF and the Receptor Sortilin in the Adult and Ageing Nervous System,” European Journal of Neuroscience 27:2103-2114. [cited by applicant]
Altmann et al., (2016). “Progranulin overexpression in sensory neurons attenuates neuropathic pain in mice: Role of autophagy,” Neurobiology of Disease, 96:294-311. [cited by applicant]
Altshuler et al., (2010). “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,” Biochemistry (Moscow), 75(13):1584-1605. [cited by applicant]
Andersen et al. (2010). “Identification of a Linear Epitope in Sortilin that Partakes in Pro-Neurotrophin Binding,” J. Biol. Chem. 285(16):12210-12222. [cited by applicant]
Angal et al. (1993). “A Single Amino Acid Substitution Abolishes The Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody,” Molecular Immunology 30(1):105-108. [cited by applicant]
Armour et al. (1999). “Recombinant Human IgG Molecules Lacking FcGamma Receptor I Binding and Monocyte Triggering Activities,” Eur. J. Immunol. 29:2613-2624. [cited by applicant]
Armour et al. (2003). “Differential Binding to Human Fcyriia and Fcγriib Receptors by Human IgG Wildtype and Mutant Antibodies,” Molecular Immunology 40:585-593. [cited by applicant]
Armour et al. (Jun. 25-28, 2000). “Mutant IgG Lacking FcγRIII Binding and ADCC Activities,” The Haematology Journal, poster Session 1, Presented at the 5th Annual Meeting of the European Haematology Association, Birming… [cited by applicant]
Arnett et al. (2007). “proNGF, sortilin, and p75NTR: Potential Mediators of Injury-Induced Apoptosis in The Mouse Dorsal Root Ganglion,” Brain Research1183:32-42. [cited by applicant]
Arrant et al., (2018). “Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis,” Journal of Neuroscience, 38:2341-2358. [cited by applicant]
Asquith et al. (2009). “Animal Models of Rheumatoid Arthritis,” Eur. J. Immunol. 39:2040-2044. [cited by applicant]
Baca et al. (1997). “Antibody Humanization Using Monovalent Phage Display,” The Journal of Biological Chemistry 272(16):10678-10684. [cited by applicant]
Baker et al. (2006). “Mutations in Progranulin Cause Tau-Negative Frontotemporal Dementia Linked to Chromosome 17,” Nature 442:916-919. [cited by applicant]
Barbas et al. (1994). “In Vitro Evolution of A Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity And Broaden Strain Cross-Reactivity,” Proc Nat. Acad. Sci. USA 9:3809-3813. [cited by applicant]
Barnes et al. (1980). “Methods for Growth of Cultured Cells in Serum-Free Medium,” Analytical Biochemistry. 102:255-270. [cited by applicant]
Bath et al. (2006). “Variant BDNF (Val66Met) impact on Brain Structure and Function,” Cognitive, Affective, & Behavioral Neuroscience 6(1):79-85. [cited by applicant]
BD Transduction Laboratories, (2008). “Purified Mouse Anti-Neurotensin Receptor 3 Product Information—Technical Data Sheet,” available online at <http://www.bdbiosciences.com/ds/pm/tds/612100.pdf>, 2 pages. [cited by applicant]
Beattie et al. (2002). “ProNGF Induces p75-Mediated Death of Oligodendrocytes following Spinal Cord Injury,” Neuron 36(3):375-386. [cited by applicant]
Birch et al., (2007). “Age-related macular degeneration: a target for nanotechnology derived medicines,” International Journal of Nanomedicine, 2:65-77. [cited by applicant]
Boerner et al. (1991). “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes,” Journal of Immunology 147(1):86-95. [cited by applicant]
Bolt et al. (1993). “The Generation of A Humanized, Non-Mitogenic Cd3 Monoclonal Antibody Which Retains In Vitro Immunosuppressive Properties,” European Journal Immunol. 23:403-411. [cited by applicant]
Bostrom et al., (2009). “Improving antibody binding affinity and specificity for therapeutic development,” Methods Mol Biol., 525:353-376. [cited by applicant]
Brennan et al. (1985). “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229:81-83. [cited by applicant]
Bruggemann et al. (1993). “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals,” Year Immunol. 7:33-40. [cited by applicant]
Cantoni et al. (2015). “Trem2 Regulates Microglial Cell Activation in Response to Demyelination In Vivo,” Acta Neuropathol, 129(3):429-447. [cited by applicant]
Cao et al. (2011). “Macrophage Polarization in The Maculae of Age-Related Macular Degeneration: A Pilot Study,” Pathology International 61:528-535. [cited by applicant]
Capel et al. (1994). “Heterogeneity of Human IgG Fc Receptors,” Immunomethods 4:25-34. [cited by applicant]
Carecchio et al. (2011). “Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers,” Journal of Alzheimer's Disease 27:781-790. [cited by applicant]
Carlo et al. (2013). “The Pro-neurotrophin Receptor Sortilin is a Major neuronal APOE Receptor for Catabolismof Amyloid-β peptide in the Brain,” J. Neurosc, 33(1):358-370. [cited by applicant]
Carrasquillo et al. (2010). “Genome-Wide Screen Identifies rs646776 near Sortilin as a Regulator of Progranulin Levels in Human Plasma,” The American Journal of Human Genetics 87:890-897. [cited by applicant]
Carter et al. (1992). “High Level [cited by applicant]
Carter et al. (1992). “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289. [cited by applicant]
Chamow et al., (1996). “Immunoadhesins: principles and applications,” Trends Biotechnol., 14:52-60. [cited by applicant]
Chang et al. (2002). “Retinal Degeneration Mutants in The Mouse,” Vision Research 42:517-525. [cited by applicant]
Chang et al., (2017). “Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation,” J Exp Med, 214:2611-2628. [cited by applicant]
Chao et al. (2006). “Isolating and Engineering Human Antibodies Using Yeast Surface Display,” Nature Protocols 1(2):755-768. [cited by applicant]
Chen et al. (2005). “Sortilin Controls Intracellular Sorting of Brain-Derived Neurotrophic Factor to the Regulated Secretory Pathway,” The Journal of Neuroscience 25(26):6156-6166. [cited by applicant]
Chesselet. (2008). “In Vivo Alpha-Synuclein Overexpression in Rodents: A Useful Model of Parkinson's Disease?,” Exp Neurol 209(1):22-27. [cited by applicant]
Chothia et al. (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol, 196:901-917. [cited by applicant]
Chu et al. (2008). “Inhibition of B Cell Receptor-Mediated Activation of Primary Human B Cells by Coengagement of CD19 and FcγRIIb With Fc-Engineered Antibodies,” Mol. Immunol. 45(15):3926-3933. [cited by applicant]
Clackson et al. (1991). “Making Antibody Fragments Using Phage Display Libraries,” Nature 352(15):624-628. [cited by applicant]
Counts et al. (2004). “Reduction of Cortical TrkA But Not p75NTR Protein in Early-Stage Alzheimer's Disease,” Ann. Neurol. 56:520-531. [cited by applicant]
Counts et al. (2005). “The Role of Nerve Growth Factor Receptors in Cholinergic BasalForebrain Degeneration in Prodromal Alzheimer Disease,” J. Neuropathol. Exp. Neurol, 64(4):263-272. [cited by applicant]
Cruts et al. (2008). “Loss of Progranulin Function in Frontotemporal Lobar Degeneration,” Trends Genetics 24(4):186-194. [cited by applicant]
Cunningham et al. (1989). “High-Resolution Epitope Mapping of Hgh-Receptor Interactions by Alanine-Scanning Mutagenesis,” Science 244:1081-1085. [cited by applicant]
Daeron (1997). “FC Receptor Biology,” Annu. Rev. Immunol. 15:203-234. [cited by applicant]
Dall'Acqua et al. (2006). “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” The Journal of Biological Chemistry 281(33):23514-23524. [cited by applicant]
Daneman et al. (2010). “The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells,” PLoS One 5(10):1-16. [cited by applicant]
Davidson et al. (2014). “A High-Throughput Shotgun Mutagenesis Approach to Mapping B-Cell Antibody Epitopes,” Immunology 143(1):13-20. [cited by applicant]
Davis et al. (2007). “Abatacept Binds to The Fc Receptor Cd64 But Does Not Mediate Complement-Dependent Cytotoxicity or Antibody-Dependent Cellular Cytotoxicity,” The Journal of Rheumatology 34(11):2204-2210. [cited by applicant]
De Haas et al. (1995). “Fcγ Receptors of Phagocytes,” J. Lab. Clin. Med. 126(4):330-341. [cited by applicant]
De Muynck, L. et al. (2013). “The Neurotrophic Properties of Progranulin Depend on the Granulin E Domain But Do Not Require Sortilin Binding,” Neurobiol Aging. 34(11):2541-2547. [cited by applicant]
Demetriades et al. (2013). “AAV-Mediated Neurotrophin-4 is Neuroprotective in Murine Model of Microbead-Induced Glaucoma with Neurotrophin Expression in the Visual Pathway,” Investigative Ophthalmology & Visual Science,… [cited by applicant]
Ducry et al. (2010). “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjug. Chem. 21(1):5-13. [cited by applicant]
Duman et al. (1997). “A Molecular and Cellular Theory of Depression,” Arch Gen Psychiatry 54(7):597-606. [cited by applicant]
Egan et al. (2003). “The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of Bdnf and Human Memory and Hippocampal Function,” Cell 112:257-269. [cited by applicant]
Egashira et al. (2013). “The Growth Factor Progranulin Attenuates Neuronal Injury Induced by Cerebral Ischemia-Reperfusion Through The Suppression of Neutrophil Recruitment,” Journal of Neuroinflammation 10(105):1-13. [cited by applicant]
El-Danaf et al. (2015). “Characteristic Patterns of Dendritic Remodeling in Early-Stage Glaucoma: Evidence from Genetically Identified Retinal Ganglion Cell Types,” The Journal of Neuroscience 35(6):2329-2343. [cited by applicant]
Estep et al. (2013). “High Throughput Solution-Based Measurement of Antibody-Antigen Affinity and Epitope Binning,” mAbs. 5(2):270-278. [cited by applicant]
Fahnestock et al. (2001). “The Precursor Pro-Nerve Growth Factor is the Predominant Form of Nerve Growth Factor in Brain and is Increased in Alzheimer's Disease,” Molecular and Cellular Neuroscience 18:210-220. [cited by applicant]
Fan. (2008). “Differential effects of Pro-BDNF on Sensory Neurons after Sciatic Nerve Transection in Neonatal Rats,” European Journal of Neuroscience 27:2380-2390. [cited by applicant]
Feldhaus et al. (2004).“Yeast Display of Antibody Fragments: A Discovery and Characterization Platform,” Journal of Immunological Methods 290:69-80. [cited by applicant]
Fellouse et al. (2004). “Synthetic Antibodies from a Four-Amino-Acid Code: A Dominant Role for Tyrosine in Antigen Recognition,” PNAS 101(34):12467-12472. [cited by applicant]
Finan. (2011). “BACE1 Retrograde Trafficking is Uniquely Regulated by the Cytoplasmic Domain of Sortilin,” The Journal of Biological Chemistry 286(14):12602-12616. [cited by applicant]
Fishwild. (1996). “High-Avidity Human Iggκ Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” Nature Biotechnology 14:845-851. [cited by applicant]
Fournier et al. (2011). “Identification of a Receptor Mediating Nogo-66 Inhibition of Axonal Regeneration,” Nature 409(6818):341-346. [cited by applicant]
Frank. (2002). “The SPOT-Synthesis Technique Synthetic Peptide Arrays on Membrane Supports—Principles and Applications,” Journal of Immunological Methods 267:13-26. [cited by applicant]
Gabathuler. (2010). “Approaches to Transport Therapeutic Drugs across the Blood-Brain Barrier to Treat Brain Diseases”, Neurobiology of Disease 37:48-57. [cited by applicant]
Galimberti et al. (2010). “GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration,” Journal of Alzheimer's Disease 19(1):171-177. [cited by applicant]
Gargini et al. (2007). “Retinal Organization in the Retinal Degeneration 10 (Rd10) Mutant Mouse: A Morphological and Erg Study,” The Journal of Comparative Neurology 500(2): 222-238. [cited by applicant]
Gerngross (2004). “Advances in the Production of Human Therapeutic Proteins in Yeasts and Filamentous Fungi,” Nature Biotechnology 22(11):1409-1414. [cited by applicant]
Gonzales et al., (2005). “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumour Biol., 26(1):31-43. [cited by applicant]
Gorno et al., (2011). “Classification of primary progressive aphasia and its variants,” Neurology, 76(11):1006-1014. [cited by applicant]
Graham et al. (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” Journal of General Virology 36(1):59-74. [cited by applicant]
Griffiths et al. (1993). “Human Anti-self Antibodies with High Specificity from Phage Display Libraries,” The EMBO Journal 12(2):725-734. [cited by applicant]
Grossniklaus et al. (2010). “Animal Models of Choroidal and Retinal Neovascularization,” Progress in Retinal and Eye Research 29(6):500-519. [cited by applicant]
Gruber et al. (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Guo et al. (2012). “Prevention of LPS-Induced Acute Lung Injury in Mice by Progranulin,” Mediators of Inflammation 2012(540794):1-10. [cited by applicant]
Gupta et al. (2003). “Activated Microglia in Human Retinitis Pigmentosa, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration,” Experimental Eye Research 76:463-471. [cited by applicant]
Gustafsen et al. (2014). “The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion,” Cell Metabolism 19:310-318. [cited by applicant]
Gustafsen. (2013). “Sortilin and SorLA Display Distinct Roles in Processing and Trafficking of Amyloid Precursor Protein,” The Journal of Neuroscience 33(1):64-71. [cited by applicant]
Ham et al. (1979). “Media and Growth Requirements,” Methods in Enzymology LVII:44-93. [cited by applicant]
Hamers-Casterman et al. (1993). “Naturally Occurring Antibodies Devoid of Light Chains.” Nature 363:446-448. [cited by applicant]
Harrington et al. (Apr. 20, 2004). “Secreted proNGF is a Pathophysiological Death-Inducing Ligand after Adult CNS Injury,” PNAS 101(16):6226-6230. [cited by applicant]
Harris. (1995). “Production of Humanized Monoclonal Antibodies for in Vivo limaging and Therapy,” Therapeutic Monoclonals, Biochemical Society Transactions 23:1035-1038. [cited by applicant]
Hawkins et al. (1992). “Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation,” Journal of Molecular Biology 226:889-896. [cited by applicant]
Hezareh et al. (2001). “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,” Journal of Virology vol. 75(24):12161-12168. [cited by applicant]
Holliger et al. (1993). ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences 90:6444-6448. [cited by applicant]
Hongo et al. (1995). “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β” Hybridoma 14(3):253-260. [cited by applicant]
Hoogenboom et al. (1992). “By-Passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline Hh Gene Segments Rearranged in Vitro,” Journal of Molecular Biology 227:381-388. [cited by applicant]
Hu et al. (2005). “Nogo—A Interacts with the Nogo-66 Receptor through Multiple Sites to Create an Isoform-Selective Subnanomolar Agonist,” The Journal of Neuroscience 25(22):5298-5304. [cited by applicant]
Hu et al. (2010). “Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin,” Neuron 68:654-667. [cited by applicant]
Hudson et al. (2003). “Engineered Antibodies,” Nat. Med. 9(1):129-134. [cited by applicant]
Hurle et al. (1994). “Protein Engineering Techniques for Antibody Humanization,” Current Opinion in Biotechnology 5:428-433. [cited by applicant]
Hutchins et al. (1995). “Improved Biodistribution, Tumor Targeting, and Reduced Immunogenicity in Mice with a Gamma 4 Variant of Campath-IH,” Proc. Natl. Acad. Sci. 92:11980-11984. [cited by applicant]
Hutton et al. (1998). “Association of Missense and 5′-Splice-Site Mutations in Tau with the Inherited Dementia FTDP-17,” Nature 393:702-705. [cited by applicant]
Jackson et al. (1995). “In Vitro Antibody Maturation. Improvement of a High Affinity, Neutralizing Antibody against IL-1 Beta,” The Journal of Immunology 157(7):3310-3319. [cited by applicant]
Jakobovits et al. (1993) “Germ-line Transmission and Expression of a Human-derived Yeast Artificial Chromosome,” Nature 362:255-258. [cited by applicant]
Jakobovits et al. (1993). “Analysis of Homozygous Mutant Chimeric Mice: Deletion of The Immunoglobulin Heavy-chain Joining Region Blocks B-Cell Development and Antibody Production,” Proceedings of the National Academy o… [cited by applicant]
Jansen et al. (2007). “Roles for the Pro-Neurotrophin Receptor Sortilin in Neuronal Development, Aging and Brain Injury,” Nature Neuroscience 10(11):1449-1457. [cited by applicant]
Jefferis et al. (2009). “Human Immunoglobulin Allotypes: Possible Implications for Immunogenicity,” MAbs 1(4):332-338. [cited by applicant]
Johnson et al. (1993). “Human antibody engineering: Current Opinion in Structural Biology,” Current Opinion in Structural Biology 3(4):564-571. [cited by applicant]
Johnson et al. (2011). “Apolipoprotein E4 Exaggerates Diabetic Dyslipidemia and Atherosclerosis in Mice Lacking the LDL Receptor,” Diabetes 60(9):2285-2294. [cited by applicant]
Jones et al. (1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,” Nature 321:522-525. [cited by applicant]
Kanazawa et al., (2015). “Multiple therapeutic effects of progranulin on experimental acute ischemic stroke,” Brain, 138:1932-1948. [cited by applicant]
Kanda et al. (2006). “Comparison of Cell Lines for Stable Production of Fucose-Negative Antibodies With Enhanced ADCC,” Biotechnol. Bioeng. 94(4):680-688. [cited by applicant]
Karch et al., (2018). “Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum,” JAMA Neurol, 75:860-875. [cited by applicant]
Kjolby et al. (2010). “Sort1, Encoded by the Cardiovascular Risk Locus 1p13.3, is a Regulator of Hepatic Lipoprotein Export,” Cell Metabolism 12:213-223. [cited by applicant]
Klinger et al. (2011). “SorLA Regulates the Activity of Lipoprotein Lipase by Intracellular Trafficking,” Journal of Cell Science 124(7):1095-1105. [cited by applicant]
Kohler et al. (1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature 256:495-497. [cited by applicant]
Kostelny et al. (1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553. [cited by applicant]
Kozbor et al. (1984). “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies,” The Journal of Immunology 133(6):3001-3005. [cited by applicant]
Kuipers et al. (2006). “Brain-Derived Neurotrophic Factor Mechanisms and Function in Adult Synaptic Plasticity: New Insights and Implications for Therapy,” Current Opinion in Drug Discovery & Development 9(5):580-586. [cited by applicant]
Kunik et al., (2012). “Structural consensus among antibodies defines the antigen binding site.” PLoS Comput Biol., 8(2):e1002388, 12 pages. [cited by applicant]
Kyte et al. (1982). “A Simple Method for Displaying the Hydropathic Character of a Protein,” J. Mol. Biol. 157(1): 105-132. [cited by applicant]
Lagier-Tourenne et al., (2009). “Rethinking ALS: the FUS about TDP-43,” Cell, 136:1001-4. [cited by applicant]
Laird et al. (2010). “Progranulin is Neurotrophic in Vivo and Protects against a Mutant TDP-43 Induced Axonopathy,” PLOS One 5(10):1-7. [cited by applicant]
Langer. (1990). “New Methods of Drug Delivery,” Science 249(4976):1527-1533. [cited by applicant]
Lauren et al. (2009). “Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers,” Nature 457:1128-1132. [cited by applicant]
Lavail et al. (2011). “Retinal Degeneration Rat Model Resource Availability of P23H and S334ter Mutant Rhodopsin Transgenic Rats and RCS Inbred and RCS Congenic Strains of Rats,” UCSF School of Medicine, 12 pages. [cited by applicant]
Lazar et al. (2006). “Engineered Antibody Fc variants with Enhanced Effector Function,” PNAS 103(11):4005-4010. [cited by applicant]
Lee et al. (2004). “Bivalent Antibody Phage Display Mimics Natural Immunoglobulin,” Journal of Immunological Methods 284:119-132. [cited by applicant]
Lee et al. (2004). “High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold,” Journal of Molecular Biology 340:1073-1093. [cited by applicant]
Lee et al. (2014). “Targeted Manipulation of the Sortilin-Progranulin Axis Rescues Progranulin Haploinsufficiency,” Human Molecular Genetics 23(6):1467-1478. [cited by applicant]
Li et al. (2006). “Human Antibodies for Immunotherapy Development Generated via a Human B Cell Hybridoma Technology,” PNAS 103(10):3557-3562. [cited by applicant]
Li et al. (2006). “Optimization of Humanized IgGs in Glycoengineered Pichia Pastoris,” Nature Biotechnology 24(2):210-215. [cited by applicant]
Lightle et al. (2010). “Mutations Within a Human IgG2 Antibody Form Distinct and Homogeneous Disulfide Isomers but do not Affect Fc Gamma Receptor or C1q Binding,” Protein Sci. 19(4):753-762. [cited by applicant]
Lipovsek et al. (2004). “In-vitro protein evolution by ribosome display and mRNA display,” Journal of Immunological Methods 290:51-67. [cited by applicant]
Lonberg et al. (1994). “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368:856-859. [cited by applicant]
Lonberg et al. (1995). “Human Antibodies from Transgenic Mice,” International Reviews of Immunology. 13:65-93. [cited by applicant]
Lonberg. (2008). “Fully Human Antibodies From Transgenic Mouse and Phage Display Platforms,” Curr. Opin. Immunol. 20(4):450-459. [cited by applicant]
Lütje et al. (2014). “Anti-CEA Antibody Fragments Labeled with [18F]AIF for PET Imaging of CEA-Expressing Tumors,” Bioconjugate Chemistry 25:335-341. [cited by applicant]
Lynaugh et al. (2013). “Rapid Fc Glycosylation Analysis of Fc Fusions with IdeS and Liquid Chromatography Mass Spectrometry,” mAbs 5:641-645. [cited by applicant]
Maguire-Zeiss. (2008). “α-Synuclein: A Therapeutic Target for Parkinson's Disease?,” Pharmacological Research 58(5-6): 271-280. [cited by applicant]
Marks et al. (1991). “By-Passing Immunization: Human Antibodies From V-Gene Libraries Displayed on Phage,” Journal of Molecular Biology 222(3): 581-597. [cited by applicant]
Marks et al. (1992).“By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Bio/Technology 10:779-782. [cited by applicant]
Martens et al. (2012). “Progranulin Deficiency Promotes Neuroinflammation and Neuron Loss Following Toxin-Induced Injury,” The Journal of Clinical Investigation 122(11):3955-3959. [cited by applicant]
Mather et al. (1982). “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Annals of the New York Academy of Sciences, Testicular Cell Culture 383:44-68. [cited by applicant]
Mather. (1980). “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biology of Reproduction 23:243-252. [cited by applicant]
McCafferty et al. (1990). “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348:552-554. [cited by applicant]
McEarchern et al. (2007). “Engineered Anti-CD70 Antibody with Multiple Effector Functions Exhibits in Vitro and in Vivo Antitumor Activities,” Blood 109(3):1185-1192. [cited by applicant]
Meeter et al., (2016). “Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers,” Dement Geriatr Cogn Disord Extra, 6:330-340. [cited by applicant]
Menzel et al., (2016). “Progranulin Protects Against Exaggerated Axonal Injury and Astrogliosis Following Traumatic Brain Injury,” GLIA, 65:278-292. [cited by applicant]
Michalski et al. (2003). “Pro-Brain-Derived Neurotrophic Factor is Decreased in Parietal Cortex in Alzheimer's Disease,” Molecular Brain Research 111:148-154. [cited by applicant]
Milstein et al. (1983). “Hybrid Hybridomas and their use in Immunohistochemistry,” Nature 305:537-540. [cited by applicant]
Minami et al. (2014). “Progranulin Protects against Amyloid β Deposition and Toxicity in Alzheimer's disease Mouse Models,” Nature Medicine 20(10):1157-1164. [cited by applicant]
Mizoguchi. (2012). “Animal models of inflammatory bowel disease,” Progress in Molecular Biology and Translational Science 105:263-320. [cited by applicant]
Morimoto et al. (1992). “Single-Step Purification of F(ab′)2 Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW,” Jour… [cited by applicant]
Morrison et al. (1984). “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains,” Proc. Nat'l Acad. Sci 81:6851-6855. [cited by applicant]
Morrison. (1994). “Success in Specification,” Nature 368:812-813. [cited by applicant]
Munson et al. (1980). “Ligand: A Versatile Computerized Approach for Characterization of Ligand-binding Systems,” Analytical Biochemistry 107:220-239. [cited by applicant]
Nakamura et al. (2007).“Intracellular Sortilin Expression Pattern Regulates proNGF-Induced Naturally Occurring Cell Death during Development,” Cell Death and Differentiation 14:1552-1554. [cited by applicant]
Neary et al. (1998). “Frontotemporal Lobar Degeneration: A Consensus on Clinical Diagnostic Criteria,” Neurology 51:1546-1554. [cited by applicant]
Neuberger. (1996). “Generating high-avidity human Mabs in mice,” Nature Biotechnology 14:826. [cited by applicant]
Neumann et al. (2007). “TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis,” Arch Neurol. 64(10):1388-1394. [cited by applicant]
Nguyen et al. (2013). “Progranulin: at the Interface of Neurodegenerative and Metabolic Diseases,” Trends in Endocrinology and Metabolism 24(12):597-606. [cited by applicant]
Nguyen et al., (2013). Trends in Endocrinology and Metabolism, 24, 597-606. [cited by applicant]
Nilsson et al. (2007).“Apolipoprotein A-V Interaction with Members of the Low Density Lipoprotein Receptor Gene Family,” Biochemistry 46(12):3896-3904. [cited by applicant]
Nilsson et al. (2008). “Endocytosis of Apolipoprotein A-V by Members of the Low Density Lipoprotein Receptor and the Vps10p Domain Receptor Families,” The Journal of Biological Chemistry 283(38):25920-25927. [cited by applicant]
NovusBio, (2020). “Datasheet: Sortilin Antibody (1B3) H00006272-M01,” Online catalogue NovusBio, May 6, 2020, available online at <https://www.novusbio.com/products/sortilin-antibody-1b3_h00006272-m01>, 4 pages. [cited by applicant]
Nykjaer et al. (2004). “Sortilin is Essential for proNGF Induced Neuronal Cell Death,” Nature 427:843-848. [cited by applicant]
Nykjaer et al. (2005). “p75NTR—Live or Let Die,” Current Opinion in Neurobiology 15:49-57. [cited by applicant]
Nykjaer et al. (2012). “Sortilin: A Receptor to Regulate Neuronal Viability and Function,” Trends in Neurosciences 35(4):261-270. [cited by applicant]
Oganesyan et al. (2008). “Structural characterization of a Human Fc Fragment Engineered for Lack of Effector Functions,” Acta Crystallography 64:700-704. [cited by applicant]
Okazaki et al. (2004). “Fucose Depletion From Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcyRIIIa,” J. Mol. Biol. 336(5):1239-1249. [cited by applicant]
Pang et al. (2004). “Cleavage of proBDNF by tPA/ Plasmin i Essential for Long-Term Hippocampal Plasticity,” Science 306:487-491. [cited by applicant]
Pedraza et al. (2005). “Pro-NGF Isolated from the Human Brain Affected by Alzheimer's Disease Induces Neuronal Apoptosis Mediated by p75NTR,” American Journal of Pathology 166(2):533-543. [cited by applicant]
Peng et al. (2005). “Precursor form of Brain-Derived Neurotrophic Factor and Mature Brain-Derived Neurotrophic Factor are Decreased in the Pre-Clinical Stages of Alzheimer's Disease,” Journal of Neurochemistry 93:1412-1… [cited by applicant]
Peng et al. (2010). “TREM2- and DAP12-Dependent Activation of PI3K Requires DAP10 and is Inhibited by SHIP1,” Science Signaling 3(122): 1-15. [cited by applicant]
Pennesi et al. (2012). “Animal Models of Age Related Macular Degeneration,” Molecular Aspects of Medicine 33(4):1-40. [cited by applicant]
Peters et al. (2012). “Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability,” The Journal of Biological Chemistry 287(29):24525-24533. [cited by applicant]
Plückthun. (1992). “Mono- and Bivalent Antibody Fragments Produced in [cited by applicant]
Presta et al. (1993). “Humanization of an Antibody Directed Against IgE,” The Journal of Immunology 151(5):2623-2632. [cited by applicant]
Presta. (1992). “Antibody Engineering,” Current Opinion in Structural Biology 2:593-596. [cited by applicant]
Provenzano. (2008). “p75NTR and Sortilin Increase After Facial Nerve Injury,” Laryngoscope 118:87-93. [cited by applicant]
Quistgaard et al. (2009). “Ligands Bind to Sortilin in the Tunnel of a Ten-Bladed β-Propeller Domain,” Nature Structural & Molecular Biology 16(1):96-98. [cited by applicant]
Quistgaard et al. (2014). “Revisiting the Structure of the Vps10 Domain of Human Sortilin and its Interaction With Neurotensin,” Protein Sci. 23(9):1291-1300. [cited by applicant]
Ratnavalli et al. (2002). “The Prevalence of Frontotemporal Dementia,” Neurology 58(1 of 2):1615-1621. [cited by applicant]
Ravetch et al. (1991). “Fc Receptors,” Annual Review Immunology 9:457-492. [cited by applicant]
Reddy et al. (2000). “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” The Journal of Immunology 164:1925-1933. [cited by applicant]
Reineke et al. (2002). “Identification of Distinct Antibody Epitopes and Mimotopes from A Peptide Array of 5520 Randomly Generated Sequences,” J. Immunol. Methods 267(1):37-51. [cited by applicant]
Riechmann et al. (1988). “Reshaping Human Antibodies for Therapy,” Nature 332:323-327. [cited by applicant]
Ripka et al. (1986). “Two Chinese Hamster Ovary Glycosylation Mutants Affected in the Conversion of GDP-Mannose to GDP-Fucose,” Arch Biochem. Biophys. 249(2):533-545. [cited by applicant]
Rizo et al. (1992). “Constrained Peptides: Models of Bioactive Peptides and Protein Substructures,” Annu. Rev. Biochem. 61:387-418. [cited by applicant]
Roberts et al. (1997). “RNA-Peptide Fusions for the In Vitro Selection of Peptides and Proteins,” Proc. Natl. Acad. Sci. USA 94:12297-12302. [cited by applicant]
Rosok et al. (1996). “Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” The Journal of Biological Chemistry 271(37):22611-22618. [cited by applicant]
Rudikoff et al., (1982). “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci., 79(6):1979-83. [cited by applicant]
Sazinsky et al. (2008). “Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors,” PNAS 105(51):20167-20172. [cited by applicant]
Schaffitzel et al. (1999). “Ribosome Display: An In Vitro Method for Selection and Evolution of Antibodies from Libraries,” Journal of Immunological Methods 231:119-135. [cited by applicant]